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Globally, lung cancer is the most commonly diagnosed form of cancer, as well as the number 
one cancer-related cause of death.  
This thesis includes four population-based studies that considered different aspects of lung 
cancer, covering incidence, diagnosis and survival.  
Study I considered the incidence of lung cancer in relation to use of antimuscarinic 
medications to treat overactive bladder. We identified first-time users of antimuscarinic 
medications and matched them with individuals not exposed to antimuscarinic medications. 
Exposed individuals had lower incidence of lung cancer than those unexposed. The inverse 
association became more pronounced over time from the start of treatment and with the 
amount of medication from filled prescriptions. Our finding of an inverse association 
generates hypotheses regarding the prevention of cancer and new treatment strategies for 
patients with cancer.  
In study II, we identified individuals with incident non-small cell lung cancer and compared 
characteristics and survival by smoking status at diagnosis. We found that women, 
adenocarcinoma, and epidermal growth factor receptor mutation were overrepresented among 
never-smokers. Furthermore, compared to current smokers, survival was longer for never-
smokers. Our findings emphasise the need for an improved understanding of lung cancer 
among never-smokers that may help to prevent lung cancer and improve survival. 
Patients with incident lung cancer were identified in study III and matched with individuals 
free of lung cancer. We investigated patterns of recent use of antibiotics as an indicator of 
early symptoms of lung cancer. We found that a diagnosis of lung cancer was associated with 
increased likelihood of recent pre-diagnostic use of antibiotics. The likelihood became more 
pronounced with the number of filled prescriptions and with proximity to the diagnosis. Our 
findings further emphasise the importance of ruling out lung cancer following pneumonia 
treatment. 
In study IV, we identified patients with incident adenocarcinoma or squamous cell 
carcinoma of the lung and investigated temporal trends in relative survival. We found that 
relative survival increased between 1995 and 2016. The increase was most pronounced 
among women, patients with stage III cancer, patients with adenocarcinoma, and never-
smokers. These findings corroborate results from other countries. The increase in relative 
survival for patients with lung cancer in recent decades can probably be attributed to the 
improvements in diagnostic procedures and new treatments. 
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Cancer is a broad group of more than 200 related diseases characterised by uncontrolled cell 
division (1, 2). Normal cells grow and divide to form new cells as they are needed by the 
body. When normal cells grow old or become damaged, they die by entering programmed 
cell death (apoptosis) and can be replaced by new cells. Cells may become damaged and 
mutated, potentially failing to respond to many of the signals that control cell growth and 
apoptosis. Compared to normal cells, the mutated cells can divide more rapidly and evade 
apoptosis. With the cell growth advantages of the mutated cells, they can make more 
replications of themselves than a normal cell can, and their offspring may outperform their 
non-mutated counterparts in the competition for resources. As more and more cells are 
created, they form a lump of cells, a tumour. The tumour continues to grow and after a while, 
it will be of a size that makes it possible to detect it. A hallmark of cancer (malignant 
tumours) is the capacity to invade surrounding tissue or spread to other organs (metastasis). 
Benign tumours are non-cancerous tumours that cannot invade surrounding tissue or 
metastasise. In 2018, more than 60,000 individuals were diagnosed with cancer in Sweden 




1.2 LUNG CANCER 
Globally, lung cancer is the most commonly diagnosed cancer with approximately 2.1 million 
new cases each year (12% of all newly diagnosed cancers), as well as the number one cancer-
related cause of death with approximately 1.8 million deaths each year (18% of cancer-
related deaths) (4). In Sweden, approximately 4,000 new lung cancer cases are diagnosed 
each year with approximately the same number of yearly deaths, making it the fourth most 
common cancer in women and the seventh most common in men and the number one cancer-
related cause of death in Sweden (3). The lung cancer incidence for Swedish men peaked in 
the 1980s (Figure 1) (5), while the incidence for women in Sweden started to level off in 
2010 (Figure 1). Today, the age-standardised lung cancer incidence in Sweden is below 20 
per 100,000 person-years for both men and women, making Sweden one of the Western 
countries with the lowest incidence, especially among men (5, 6).  





Based on histopathology, lung cancer is divided into two main groups: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) (7, 8). NSCLC accounts for approximately 
80% of all lung cancer cases and will be the main focus of this thesis. Adenocarcinoma and 
squamous cell carcinoma are the two main forms of NSCLC. The different types of lung 
cancer arise from different cell types in the epithelium of the lung.  
Adenocarcinoma arises from the epithelium in the early stage of the gland (adenoma) cells 
(7-12). Adenocarcinoma of the lungs tends to start in the more peripheral part of the lung 
(alveoli) and is generally characterised by slower growth compared to other types of lung 
cancer. Adenocarcinoma is overrepresented in never-smokers, women and younger patients. 
Driver gene alterations, for example, epidermal growth factor receptor (EGFR) mutation, 
Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation, and gene fusions of 
anaplastic lymphoma kinase (ALK) or ROS1, occur more often in patients with 
adenocarcinoma compared to other histopathological subtypes of lung cancer. The proportion 
of patients with adenocarcinoma has increased over time, and today, more than 50% of the 
patients with lung cancer in Sweden have adenocarcinoma, making it the most common 
subtype of lung cancer (13). 
Squamous cell carcinoma is cancer that begins in squamous cells, often in a main or lobar 
bronchus of the lung; it tends to be locally aggressive and may invade local structures (7-12). 
Compared to adenocarcinoma, oncogene driver alterations are rare in squamous cell 
carcinoma. However, a mutation in the TP53 gene is more common in squamous cell 
carcinoma. Squamous cell carcinoma is overrepresented among ever-smokers, men and older 
patients. Currently, squamous cell carcinoma is the second most common subtype of lung 
cancer; approximately 20% of patients with lung cancer in Sweden have squamous cell 
carcinoma, and the proportion has been fairly stable in recent years (13).  
SCLC is a centrally located tumour type that starts in neuroendocrine-cell precursors of the 
lung (7, 8, 10). SCLC is the subtype of lung cancer with the most pronounced association 
with smoking, almost 100% of patients with SCLC are current or former smokers. Oncogene 
driver alterations are rare in SCLC. Approximately 15% of the patients with lung cancer in 





Cancer stage at diagnosis is a well-established indicator of disease severity and prognosis 
(14-17). In this thesis, stage at diagnosis is based on the tumour-node-metastasis (TNM) 
classification system by the American Joint Committee on Cancer, using the fourth edition 
from 1992, the fifth edition from 1997, the sixth edition from 2002, and the seventh edition 
from 2010 onwards. The T-descriptor refers to the size and localisation of the tumour, the N-
descriptor describes the involvement of the lymph nodes, and the M-descriptor refers to the 
presence of metastasis. The specific characteristics of the descriptors within the seventh 
edition are presented in Table 1. The changes between editions tend to mainly involve refined 
divisions of the T-descriptor. One substantial change from the sixth to the seventh edition was 
that pleural effusion was reclassified from T4 to M1. The T-, N- and M-descriptors are 
grouped in different combinations to ascertain the cancer stage, ranging from I to IV. The 
different combinations for the seventh edition are presented in Table 2.  
Table 1. Description of the tumour-node-metastasis (TNM) descriptors for lung cancer in the seventh edition 
of the TNM classification system by the American Joint Committee on Cancer  
Descriptor Description 
T: Primary tumour size and location  
TX 
Primary tumour cannot be assessed or tumour proven by the 
presence of malignant cells in sputum or bronchial washings but not 
visualised by imaging or bronchoscopy 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 
Tumour <3 cm in greatest dimension, surrounded by lung or visceral 
pleura, without bronchoscopy evidence of invasion more proximal 
than the lobar bronchus (i.e. not in the main bronchus) 
T1a Tumour <2 cm in greatest dimension 
T1b Tumour >2 cm but <3 cm in greatest dimension 
T2 
Tumour >3 cm but <7 cm or tumour with any of the following 
features (T2 tumours with these features are classified T2a if <5 cm): 
 Involves main bronchus, >2 cm distal to the carina 
 Invades visceral pleura 
 Associated with atelectasis or obstructive pneumonitis 
that extends to the hilar region but does not involve the 
entire lung 
T2a Tumour >3 cm but <5 cm in greatest dimension 
T2b Tumour >5 cm but <7 cm in greatest dimension 
T3 
Tumour >7 cm or one that directly invades any of the following: 
 Chest wall (including superior sulcus tumours), 
diaphragm, phrenic nerve, mediastinal pleura, parietal 
pericardium 
 Tumour in the main bronchus <2 cm distal to the carina 
but without involvement of the carina 
 Associated atelectasis or obstructive pneumonitis of the 
entire lung 
 Separate tumour nodule(s) in the same lobe 
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Table 1. Description of the tumour-node-metastasis (TNM) descriptors for lung cancer in the seventh edition 
of the TNM classification system by the American Joint Committee on Cancer  
Descriptor Description 
T4 
Tumour of any size that invades any of the following: 
 Mediastinum, heart, great vessels, trachea, recurrent 
laryngeal nerve, oesophagus, vertebral body, carina 
 Separate tumour nodule(s) in a different ipsilateral lobe 
to that of the primary tumour 
N: Regional lymph nodes  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 
Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph 
nodes and intrapulmonary nodes, including involvement by direct 
extension 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 
Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral 
or contralateral scalene, or supraclavicular lymph node(s) 
M: Distant metastases  
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a 
Separate tumour nodule(s) in a contralateral lobe, tumour with 
pleural nodules or malignant pleural (or pericardial) effusion 
M1b Distant metastasis in extrathoracic organ(s) 
 
Table 2. Stage according to the seventh edition of the tumour-node-metastasis (TNM) classification system for 
lung cancer by the American Joint Committee on Cancer  
T/M N0 N1 N2 N3 
T1a IA IIA IIIA IIIB 
T1b IA IIA IIIA IIIB 
T2a IB IIA IIIA IIIB 
T2b IIA IIB IIIA IIIB 
T3 IIB IIIA IIIA IIIB 
T4 IIIA IIIA IIIB IIIB 





1.2.3 Performance status (PS) 
PS is a standard measure for the general health status of patients with cancer and of how the 
disease impacts the daily life of the patient (18). According to the World Health Organization 
(WHO), PS is graded from 0 to 5 as described in Table 3. 
Table 3. World Health Organization performance status  
Grade Description 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g. light housework, office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities; up and 
about more than 50% of waking hours 
3 Capable of only limited self-care; confined to bed or chair more than 50% of waking hours 




In addition to concluding that it is lung cancer, the diagnostic procedure aims to ascertain the 
histopathology, genetic alterations, cancer stage and PS (19). All these components of the 
diagnosis are of great importance when deciding on treatment strategy.  
Diagnostic procedures 
Since 2016, there has been a standardised course of care for lung cancer in Sweden that aims 
to standardise the course of care throughout the whole of Sweden (20). It includes a set of 
recommended investigative activities and recommended maximum lead times from a well-
founded suspicion of lung cancer to start of treatment. However, there is still a long way to go 
until the recommended lead times are reached for >80% of the patients (Table 4) (21).  
Table 4. Lead time from a well-founded suspicion of lung cancer to start of treatment  
 Maximum1 Median (percentage within maximum)2 
Treatment  2016 2017 2018 
Surgery 44 73 (20) 72 (13) 71 (10) 
Radiotherapy 44 48 (46) 69 (27) 70 (27) 
Chemotherapy/medical treatment 40 40 (51) 43 (44) 49 (37) 
Palliative symptom relief care 30 26 (61) 28 (53) 29 (52) 
Data presented: median lead time in days (percentage within the maximum lead time as recommended in the standardised course of care) 
 
1 Maximum lead time in days from a well-founded suspicion of lung cancer to start of treatment as recommended in the standardised course of care. 
2 Reported lead time in days from a well-founded suspicion of lung cancer to start of treatment.  
 
Newly presented respiratory symptoms that are persistent for longer than six weeks among 
smokers or former smokers over the age of 40, unexplainable chest or shoulder pain or 
haemoptysis should cause suspicion of lung cancer (19, 22). For never-smokers, these 
symptoms should cause suspicion of lung cancer in the absence of other explanations. 
Individuals with suspected lung cancer should be referred to undergo a lung X-ray or 
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computed tomography (CT) of the lungs. Pathological findings from an initial lung X-ray or 
CT, recurrent haemoptysis, metastatic findings that give rise to suspicion of lung cancer, 
superior vena cava obstruction or vocal cord paralysis should give rise to a well-founded 
suspicion of lung cancer, and these patients should be referred to a specialist clinic for further 
examination. However, when symptoms are starting to present, the lung cancer has usually 
metastasised, which is the case for the majority of newly diagnosed cases (13). Typically, 
early detection is often an accidental finding after radiology was indicated for other reasons. 
All patients should undergo a clinical examination including auscultation and percussion of 
the lungs, auscultation of the heart, measurement of the blood pressure, palpation of the 
supraclavicular lymph nodes and palpation of the abdomen (19). A correct clinical 
examination is an important first step when assessing the cancer stage. 
Examination with CT in combination with positron emission tomography (PET), required for 
a more precise diagnosis concerning metastases and tumour size, is recommended for patients 
considered for curative treatment (13, 19). The use of PET-CT started in 2007 and has 
increased over time; in 2016, almost 100% of the patients considered for curative treatment 
had undergone an examination with PET-CT as a part of their diagnostic procedure. Due to 
the low risk of metastases, patients with stage IA are not included in the recommendations 
regarding PET-CT. 
Bronchoscopy is a part of the routine diagnostic procedure and aims to assess the 
endobronchial expansion and to verify the diagnosis by taking a biopsy (pathological 
diagnosis) and/or sampling cells by scraping or brushing (cytological diagnosis) (19). 
Conventional bronchoscopy works best for central tumours, while if the tumour is peripheral, 
one can perform CT- or ultrasound-guided transthoracic fine needle aspiration or core biopsy. 
The collected tissue can also be used for molecular profiling of the tumour. For patients with 
squamous cell carcinoma, testing is recommended for at least the programmed cell death 
protein ligand 1 (PD-L1), while for patients with other forms of NSCLC, in addition to 
testing for PD-LI, testing is recommended for different driver gene alterations, for example, 
EGFR mutation, KRAS mutation, and rearrangement of ALK and ROS1. 
In patients considered for curative treatment, bronchoscopy can be combined with 
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) (19). 
EBUS-TBNA is the recommended bronchoscopy method for sampling from mediastinal 
lymph nodes and should be performed after a PET-CT has been performed. Mediastinal 
sampling is recommended for these patients in the case of abnormal lymph nodes detected on 




1.2.5 Aetiology and risk factors 
Tobacco use  
Tobacco smoking is the main risk factor for lung cancer and has been estimated to cause 
>80% of all lung cancer cases in high-income countries, with a lower corresponding 
proportion in many low- and middle-income countries (8, 23, 24). The prevalence of smoking 
peaked earlier among men and in high-income countries compared to women and people in 
low- and middle-income countries. Because of the long latency period, incidence trends of 
lung cancer reflect smoking prevalence 20–30 years earlier (25, 26). The International 
Agency for Research on Cancer (IARC) has identified more than 50 different carcinogenic 
substances present in tobacco smoke (27, 28). The mechanism of these substances involves, 
for example, creation of free radicals that cause DNA damage in lung cells, subsequently 
resulting in cancer development. 
The association between tobacco smoking and lung cancer has been reported in several 
epidemiological studies since the early 1950s (29, 30). The excess risk of lung cancer 
comparing regular smokers to never-smokers is approximately tenfold, with a more 
pronounced magnitude with increasing daily cigarette consumption and an indication of a 
more pronounced magnitude for women compared to men (31). 
Although the evidence is strongest for first-hand smoking, there is also an observed 
association between second-hand smoking and lung cancer (32). It was estimated in a meta-
analysis that compared to not living with a smoker, the excess risk of lung cancer in never-
smokers who lived with a smoker was 24%. 
The use of electronic cigarettes as a tobacco-free alternative to regular cigarettes is increasing 
(33, 34). Compared to regular cigarettes, electronic cigarettes produce fewer toxic and 
carcinogenic substances. However, the high temperature in the vapour still generates many 
toxic substances that are classified as carcinogenic to humans. Today, the long-term 
carcinogenic effect of electronic cigarette use remains unknown.  
Studies that investigated the association between use of smokeless tobacco and lung cancer 
have reported inconclusive results, with an indication of a positive association reported in 
studies from the United States of America (USA) and indications of an inverse association in 
studies from Norway and Sweden (35). These differences may be attributed to differences in 




Radon, a naturally occurring radioactive noble gas resulting from the decay of uranium-238, 
was established as the first environmental lung carcinogen (36, 37). Radon decays in the 
lungs and emits alpha radiation, resulting in DNA damage and subsequent tumour 
development. It is estimated that indoor radon exposure contributes to approximately 10% of 
new cases of lung cancer (19). However, Swedish case-control studies have estimated an 
increased risk among smokers only, suggesting a synergistic effect between radiation and 
tobacco smoking (38, 39).  
Asbestos  
Asbestos, which consists of silicate mineral fibres, was first used commercially in the late 
19th century, with a peak between the 1950s and 1970s in high-income countries (40-43). 
Asbestos is the most common occupational cause of lung cancer, WHO has estimated that 
approximately 125 million people worldwide are exposed to asbestos in an occupational 
setting. In the 1930s, the link between asbestos and lung cancer was hypothesised. However, 
it was not until the 1950s that asbestos became recognised as a lung carcinogen after 
observational studies on industrial workers in the United Kingdom.  
Air pollution 
The combined evidence suggests a positive association between outdoor air pollution and 
lung cancer, and the IARC has classified outdoor air pollution as a lung carcinogen in 
humans (44). A meta-analysis including 17 studies from nine European countries found an 
association between exposure to particulate matter (PM) with a diameter smaller than 10 μm 
(PM10) and lung cancer, with an increased risk of approximately 20% per every 10 μg/m
3 
increase in PM10 concentration (45).  
Infections 
Lung cancer has mainly been associated with infections of the respiratory system. In a meta-
analysis including 41 studies, tuberculosis (TB) infection was associated with increased 
incidence of lung cancer (46). The association was most pronounced between one and five 
years after the TB infection and declined over time. However, a positive association was still 
observed 20 years after the TB infection. Moreover, Chlamydia pneumoniae has been 
associated with an increased risk of a lung cancer diagnosis (47). All six studies in a review 
from 2005 reported a positive association. However, it is important to consider that 
respiratory infections are the most common differential diagnoses of lung cancer. This can 
introduce bias leading to a stronger association due to the fact that early symptoms of lung 
cancer can be misdiagnosed as a respiratory infection. 
Three major mechanisms of infectious agent-mediated cancer are often suggested (48). The 
first is the induction of a chronic inflammatory environment as a consequence of a continuing 
immune response to a persistent infection. The second mechanism is virus-induced 
transformation, which causes a change in growth, phenotype or replication of cells. The third 




Different pharmacological treatments (e.g. angiotensin-converting enzyme [ACE] inhibitors, 
antibiotics and aspirin) have been assessed for association with lung cancer incidence in 
observational studies. 
ACE inhibitors, which are medications used in the treatment of hypertension, have been 
associated with an increased risk of different cancers, including lung cancer. A large cohort 
study in 2018 with data on almost one million individuals from the United Kingdom treated 
for hypertension found that compared to angiotensin receptor blocker (ARB) use, use of ACE 
inhibitors was associated with a 14% increased risk of lung cancer (49).  
Two studies using data from the United Kingdom estimated increased odds (approximately 
30%) of lung cancer associated with antibiotic use (50, 51). It is hypothesised that the 
association between antibiotic use and an increased risk of lung cancer is mediated by 
suppression of the normal anti-tumour response in the cells or a change in the composition of 
the human microbiota (52).  
A meta-analysis of 15 studies estimated an inverse association between use of aspirin and 
lung cancer incidence (approximately 15% lower risk) (53). The magnitude of the inverse 
association was more pronounced for case-control studies than for cohort studies, suggesting 
a possible role of recall bias.  
Diet 
The topic of diet and lung cancer risk is controversial with conflicting results (54). 
Antioxidants are found in many fruits and vegetables and act as electron donors which 
neutralise free radicals that can cause DNA damage and promote tumour development. There 
is some evidence from epidemiological studies that a diet rich in fruits and vegetables is 
associated with lower incidence of lung cancer, while it has been suggested that a high intake 
of red or processed meat can increase the risk of lung cancer. If the association is real, it may 
be explained by the formation of nitrosamines when preparing the meat at high temperatures, 





Several studies have assessed the role of family history in lung cancer. A case-control study 
with pooled data on 24,380 patients with lung cancer and 23,399 individuals free of lung 
cancer from The International Lung Cancer Consortium estimated that having a first degree 
relative with lung cancer was associated with a 1.5-fold increase in the odds of lung cancer 
(55). The magnitude of the effect size for the association was more pronounced in the Asian 
population, for patients diagnosed with lung cancer before the age of 50, and for siblings 
compared to parents. The stronger association for siblings is probably attributed to shared 
environmental childhood exposure or an indication that recessive genes are involved.  
Genetic factors 
Mutation in the TP53 gene is one of the most frequent mutations in patients with lung cancer, 
more than 50% of whom have a mutation in the TP53 gene. Mutation frequency increases 
with the duration of smoking and is more common in squamous cell carcinoma than in 
adenocarcinoma (8). Other relatively common alterations of genes involved in lung cancer 
are mutations in EGFR and KRAS, and rearrangements in ALK and ROS1. The prevalence of 
these alterations is less common among patients with non-adenocarcinoma. Among patients 
with adenocarcinoma, 10–15% have an EGFR mutation, 25–40% have a mutation in KRAS, 
2–10% have a rearrangement of the ALK gene, and 1% have a rearrangement of the ROS1 
gene.  
Sex 
The increased risk of cancer in men has been observed for many cancers, including lung 
cancer, with decreasing difference over time (56-58). The observed discrepancy in incidence 
between men and women is often explained by differences in environmental exposures, for 
example, tobacco smoking, radon, asbestos, diet, and air pollution. Furthermore, innate risk 
factors have been proposed as potential reasons for the sex-based discrepancy, for example, 
the total number of cells, sex hormones, and immunological factors (11, 58, 59). Today, lung 
cancer is more common among women than men in Sweden, most probably due to changes 





The treatment strategy for lung cancer depends mainly on four factors: histopathology, 
genetic alterations, cancer stage, and PS (19, 60).  
Surgery 
The first successful restriction of a lung tumour by removing an entire lung (pulmectomy) 
was performed in 1933 by Graham and Singer (61). Today, a surgical restriction is the 
preferred curative treatment for patients with NSCLC with stages I and II but can also be 
considered for some patients with stage IIIA (19, 60). In patients with stage IIIB, surgery is 
mostly considered not feasible because of an invasion of the mediastinal structure of the 
vertebrae (T4) or substantial involvement of lymph nodes (N3). In general, there is no place 
for surgery in patients with stage IV cancer. However, it can be considered for selected cases, 
for example, in the case of a single metastasis in the brain or the adrenal glands. The type of 
surgical restriction is dependent on the location, size and spread of the tumour and the PS of 
the patient. Currently, about 80% of all surgical restrictions of patients with lung cancer are 
lobectomies or bilobectomies, where one or two lung lobes are removed respectively. 
Surgical restriction of lung tumours is performed either with open thoracotomy or by video-
assisted thoracic surgery (VATS). Proper staging, to exclude mediastinal and extrathoracic 
metastases, and assessment of the patients’ PS, lung function and comorbidities, should be 
done before a decision on surgery can be made.  
Platinum-based chemotherapy can be given to patients with NSCLC who undergo a complete 
tumour restriction, either as neoadjuvant chemotherapy (i.e. chemotherapy is given prior to 
the surgery) or as adjuvant chemotherapy (i.e. chemotherapy is given after surgery) (19). The 
reason for giving neoadjuvant chemotherapy is mainly to reduce the tumour size prior to 
surgery, while the rationale for giving adjuvant chemotherapy is to eliminate micrometastases 
to reduce the risk of relapse. The benefit of adjuvant chemotherapy after surgery is well-
established for patients with stages IB–IIIA (60, 62, 63). A pooled analysis published in 2008 
by Pignong et al with 4,584 patients from five randomised controlled trials (RCTs) estimated 
longer overall survival associated with adjuvant chemotherapy after surgery compared to 
surgery alone (hazard ratio [HR] = 0.89, 95% confidence interval [CI]: 0.82–0.96) (62). For 
the patients with stage IA, an indication of shorter survival was estimated for the patients 
receiving adjuvant chemotherapy compared to surgery alone (HR = 1.40, 95% CI: 0.95–
2.06). Another meta-analysis published in 2010 with 34 RCTs that assessed the same 
question estimated longer overall five-year survival associated with adjuvant treatment (64% 
and 60% respectively; HR = 0.86, 95% CI: 0.81–0.92), also indicating shorter survival for 
patients with stage IA (HR = 1.19, 95% CI: 0.84–1.68) (63). Neoadjuvant treatment has also 
been assessed, and a meta-analysis with data from ten RCTs including 2,188 patients with 
NSCLC in stages IB–IIIA reported prolonged survival associated with receiving neoadjuvant 
chemotherapy compared to surgery alone (HR = 0.89, 95% CI: 0.81–0.98) (64). A study from 
the USA that compared survival between neoadjuvant and adjuvant chemotherapy in 35,134 
patients with NSCLC in stages II–III estimated lower hazard of death associated with 
adjuvant therapy (stage II – median overall survival: 81 and 67 months respectively; HR = 
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0.75, 95% CI: 0.65–0.88, and stage III – median overall survival: 49 and 42 months 
respectively; HR = 0.80, 95% CI: 0.70–0.91) (65).  
Based on current knowledge, patients with NSCLC, except stage IA, who undergo a 
complete tumour restriction should be offered platinum-based chemotherapy in addition to 
surgery (19). The standard treatment approach in Sweden is a platinum-based combination 
given as adjuvant chemotherapy in four cycles that should be initiated within eight weeks 
after surgery.  
Radiotherapy 
Patients with NSCLC in stages I and II who are inoperable because of, for example, 
comorbidity, poor PS or an unfavourable location of the tumour, should be treated with 
stereotactic body radiotherapy (SBRT) (19, 60). Compared to conventional radiotherapy, 
SBRT uses high doses of radiation delivered to a very precise area. The first RCT comparing 
SBRT and conventional radiotherapy among inoperable patients with stage I NSCLC, 
published in 2016, reported that there was no estimated difference in either progression-free 
survival (HR = 0.85, 95% CI: 0.52–1.36) or overall survival (HR = 0.75, 95% CI: 0.43–1.30) 
(66). However, SBRT was associated with a better quality of life and less toxicity. An 
observational study from 2018 that included more than 20,000 patients with NSCLC in stage 
I from the USA reported longer overall survival associated with SBRT compared to 
conventional radiotherapy (median overall survival: 39 and 28 months respectively; HR = 
0.73, 95% CI: 0.69–0.77) (67). 
Combined radio-chemotherapy is the standard treatment for curative intent in patients with 
inoperable NSCLC in stage III (19, 68). The combination can be given sequentially (starting 
with chemotherapy and subsequent radiotherapy) or concomitantly (chemotherapy and 
radiotherapy are given at the same time). The aim of sequential therapy is mainly to reduce 
the frequency of micrometastases and to reduce the tumour size prior to radiotherapy, while 
the aim of concomitant therapy is mainly to achieve a high locoregional control. In terms of 
survival, concomitant treatment is considered superior to sequential treatment (68-70). In 
Sweden, the current recommendation for combined radio-chemotherapy is to give 
concomitant radio-chemotherapy with three cycles of a platinum-based regime, and 
radiotherapy is added from the second cycle onwards (19). However, concomitant therapy is 
also associated with a higher occurrence of severe oesophageal toxicity. Therefore, patients 
with poor PS or comorbidity should receive sequential therapy. 
Chemotherapy and immunotherapy 
Chemotherapy can be given with either curative or palliative intent. When given with 
curative intent, it is given in combination with surgery or radiotherapy, as described above. 
This section will focus on chemotherapy given with palliative intent.  
Chemotherapy and immunotherapy are presented together in this section as their indications 
highly overlap. In general, they are indicated for patients with late-stage (IIIB–IV) NSCLC 
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without targetable alterations, such as EGFR mutation or ALK or ROS1 rearrangements (19, 
71).  
In recent decades, platinum-based chemotherapy has been the cornerstone in the palliative 
treatment of patients with late-stage NSCLC (19, 72, 73). However, because of the limited 
efficacy and significant toxicity in the early days of chemotherapy, the use of chemotherapy 
was a controversial issue until the 1990s. A meta-analysis from 1995 with eight RCTs 
including a total of 778 patients with late-stage NSCLC estimated that treatment with 
platinum-based chemotherapy was associated a 27% lower hazard of death compared to 
treatment with best supportive care alone, equivalent to an increase in one-year survival from 
5% to 15% (73). These results were later confirmed by an updated meta-analysis published in 
2008, which included 16 RCTs and a total of 2,714 patients (HR = 0.77, 95% CI: 0.71–0.83) 
(72). In terms of survival, there is an indication that carboplatin-based regimes are associated 
with a slightly lower survival compared to cisplatin (HR = 1.07, 95% CI: 0.99–1.15) (74). 
Furthermore, a higher response rate was found among patients treated with cisplatin 
compared to carboplatin. However, thanks to their more favourable toxicological profile, 
carboplatin-based regimes are becoming more common in palliative care (19, 74). The 
optimal number of treatment cycles with platinum-based chemotherapy in first-line treatment 
for patients with late-stage NSCLC has been investigated in different meta-analyses. There is 
no strong evidence for prolonged overall survival associated with more than four cycles of 
chemotherapy (75-77). However, there is evidence for prolonged progression-free survival, 
as well as an indication of more adverse events and more impaired quality of life in patients 
treated with more than four cycles. 
The involvement of the immune system in cancer development has been known for a long 
time. The programmed cell death protein 1 (PD-1) is a receptor expressed on the surface of 
activated T-cells and its ligand, PD-L1, is expressed on the surface of different immune cells 
(78). To avoid chronic autoimmune response, the interaction between PD-1 and PD-L1 
inhibits the T-cell response and ensures that the immune response mediated by T-cells is 
activated only when appropriate. PD-L1 is often overexpressed on tumour cells, resulting in 
pronounced inhibition of the immune system by the tumour. Immunotherapy is the newest 
choice in the treatment of patients with lung cancer and has recently led to changes in 
recommendations of treatment for patients with late-stage NSCLC. Immunotherapy acts by 
binding to the PD-1 receptor, thereby preventing the interaction between PD-1 and PD-L1; 
this will result in activation of the immune system that can identify and eliminate the tumour.  
Immunotherapy as monotherapy in treatment-naïve patients with late-stage NSCLC and PD-
L1 expression ≥50% has been reported to be associated with longer survival when compared 
to the patients treated with platinum-based chemotherapy (79). Furthermore, combination 
therapy of platinum-based chemotherapy and immunotherapy in treatment-naïve patients 
with late-stage NSCLC has been associated with longer survival when compared to platinum-
based chemotherapy alone (80, 81). The prolonged survival associated with the combination 
therapy was independent of PD-L1 expression degree. 
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Based on current knowledge, combination therapy of platinum-based chemotherapy and 
immunotherapy is recommended for patients with late-stage NSCLC without targetable 
alterations such as EGFR mutation or rearrangements of the ALK or ROS1 genes and with a 
WHO PS <2 (19). It is recommended for patients in this group with expression of PD-L1 
≥50% that immunotherapy is given as monotherapy, while patients with a WHO PS of 2 or 
patients with increased risk of complications from immunotherapy should be given platinum-
based chemotherapy as monotherapy. Upon progression for patients undergoing platinum-
based chemotherapy as monotherapy, one should consider changing to treatment with 
immunotherapy as monotherapy. If there is progression for patients on immunotherapy given 
as monotherapy, switching to platinum-based chemotherapy is an option, while for patients 
who progress after combination therapy, switching to docetaxel or pemetrexed can be an 
alternative.  
Tyrosine kinase inhibitors (TKIs) 
EGFR is a transmembrane growth factor receptor that serves as a mediator of extracellular 
growth factors (82). The receptor is involved in cell growth, proliferation and apoptosis. A 
mutation in the tyrosine kinase domain of the receptor can result in increased downstream 
activity of pro-survival functions of the cell, such as increased cell proliferation and inhibition 
of apoptosis. The EGFR-TKIs bind to the mutated tyrosine kinase domain and prevent the 
downstream signalling, resulting in inhibition of the cell proliferation and induction of cell 
death by the normal apoptotic pathway. Several RCTs have reported prolonged progression-
free survival, a higher response rate and a more distinct improvement in the quality of life 
associated with EGFR-TKI compared to platinum-based chemotherapy in treatment-naïve 
patients with late-stage NSCLC with EGFR mutation (83-87). However, clear prolongation in 
overall survival has been more difficult to find. The combination of EGFR-TKI and 
platinum-based chemotherapy compared to EGFR-TKI alone in this patient group was 
associated with prolonged overall survival and higher occurrence of adverse events (88).  
A meta-analysis with five RCTs that included a total of 660 patients with EGFR-mutated 
NSCLC in stages I–IIIA estimated that treatment with adjuvant EGFR-TKI after surgery was 
associated with longer disease-free survival (i.e. time from randomisation to recurrence of 
tumour or death) compared to surgery alone (HR = 0.48, 95% CI: 0.36–0.65) (89). An 
indication of longer overall survival associated with adjuvant EGFR-TKI treatment was also 
found (HR = 0.72, 95% CI: 0.49–1.06).  
ALK is a transmembrane tyrosine kinase receptor (90). Most alterations of ALK genes result 
in fusion genes, for example, with EML4, resulting in the EML4-ALK fusion gene where the 
extracellular and intramembranous parts of the ALK are replaced with EML4. ALK fusions 
can lead to alteration of the kinase activity, and subsequently an increase in cell proliferation 
and inhibition of apoptosis. ALK-TKIs act by blocking the tyrosine kinase activity, resulting 
in a reduction of the cell proliferation and induction of the intrinsic apoptosis. It has been 
reported that compared to platinum-based chemotherapy, ALK-TKIs are associated with 
prolonged progression-free survival, a higher objective response rate and a greater 
improvement in the quality of life in treatment-naïve patients with ALK-positive late-stage 
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NSCLC (91, 92). Similar to EGFR-TKIs, a prolongation in overall survival has been difficult 
to find, probably due to the high number of patients switching treatment upon disease 
progression.  
Based on current knowledge, patients with late-stage NSCLC should undergo treatment with 
an EGFR-TKI if they have an EGFR mutation and with an ALK-TKI if they have a 
rearrangement in the ALK gene (19). Furthermore, it is recommended that patients with the 
rare ROS1 rearrangement should undergo treatment with an ALK-TKI. Upon disease 
progression on TKIs, one may first consider other TKIs for the same alteration. However, 
platinum-based chemotherapy can be an option and should in those situations be given as 
described above.  
Anti-angiogenesis 
Angiogenesis refers to the formation of new blood vessels that are responsible for the supply 
of oxygen and nutrition to the tumour (2). Solid tumours cannot grow larger than 2–3 mm or 
metastasise without forming their own blood vessels, making tumour angiogenesis a hallmark 
of cancer. Vascular endothelial growth factor (VEGF) is the key mediator of angiogenesis, as 
it binds to the VEGF receptors. Upregulation of VEGF is a response to hypoxia, which is 
common in cancer, resulting in angiogenesis.  
Bevacizumab, a monoclonal antibody, binds to VEGF and thereby prevents it from binding to 
the receptor, resulting in inhibition of angiogenesis (93). In patients with late-stage 
adenocarcinoma, not eligible for a TKI therapy, treatment with bevacizumab in combination 
with platinum-based chemotherapy has been associated with prolonged progression-free 






Survival for patients diagnosed with lung cancer is generally low (98). In most countries, 
between 2010 and 2014, the overall five-year relative survival was estimated at between 10% 
and 20%. In Sweden, it was estimated at 20%, and the highest estimated overall five-year 
relative survival was in Japan at 33%.  
Prognostic factors 
A prognostic factor is a factor that is associated with the natural history of the disease, 
namely progression-free survival or overall survival independent of the treatment given (99, 
100). Prognostic factors in lung cancer encompass both tumour-related factors, for example, 
cancer stage at diagnosis (101), histopathology (102) and genetic alterations (103-105), and 
patient-related factors, for example, PS (102, 106), sex (102, 107, 108), age (102), 
socioeconomic status (109) and smoking status (102, 110-112).  
Cancer stage 
Cancer stage at diagnosis is probably the most important prognostic factor in patients with 
lung cancer. For the eighth edition of the TNM classification, data on more than 90,000 
patients diagnosed with lung cancer between 1999 and 2010 from 16 countries was analysed 
(101). The reported five-year survival varied between 92% for patients in the earliest stage 
and 0% for patients with multiple distant metastases.  
Histopathology 
The prognostic value of histopathology is unclear due to conflicting results. Five of 31 studies 
in a comprehensive review that assessed histopathology as a prognostic factor in patients with 
NSCLC reported a difference in prognosis by histopathology (102). Of these five studies, 
longer survival was associated with adenocarcinoma in four and with squamous cell 
carcinoma in one.  
Genetic alterations 
The prognostic value of several genetic alterations has been studied, for example, it has been 
suggested that the wild-type of the TP53, EGFR and KRAS genes is associated with a more 
favourable prognosis (103-105). Although a large number of studies have assessed the 
prognostic impact of TP53 mutation, the results are inconsistent, mainly because of relatively 
small study populations. A systematic review and meta-analysis published in 2001 by Steels 
et al which included 67 studies assessing survival by TP53 mutation status in patients with 
NSCLC reported that 30 studies identified TP53 mutation as a negative prognostic factor 
(103). It was estimated that having a TP53 mutation was associated with shorter survival of 
patients compared to those with a wild-type of the TP53 gene (HR = 1.40, 95% CI: 1.20–
1.72). Meert et al conducted a meta-analysis of 11 studies assessing the prognostic impact of 
EGFR mutation and reported an HR for death of 1.14 (95% CI: 0.94–1.39) by comparing 
patients with a mutation to patients with a wild-type (104). Meng et al included 41 studies in 
a meta-analysis assessing the prognostic impact of mutation of the KRAS gene and reported 




Despite the subjective aspects of PS, it is considered one of the strongest prognostic factors in 
lung cancer (102, 106). The association between PS and survival in patients with lung cancer 
has been consistently found in studies from different settings and periods. A systematic 
review with studies published between 2000 and 2010 identified 49 studies assessing the 
prognostic value of PS, of which 36 found that good PS was associated with longer survival 
(102). Kawaguchi et al analysed data from 26,957 individuals diagnosed with lung cancer in 
Japan and found a trend of increased hazard of death with increasing WHO PS (i.e. with 
poorer PS) (106). A WHO PS of 1 was associated with approximately 30% higher hazard of 
death compared to a WHO PS of 0, while the corresponding estimate for a WHO PS of 4 was 
300%.  
Sex 
There is a large body of evidence supporting longer survival in women compared to men 
after a diagnosis of lung cancer (102, 107, 108). A systematic review with 45 studies which 
assessed sex as a prognostic factor reported that 17 of the studies estimated that being a 
woman was associated with longer survival, while the remaining 28 had not been able to 
observe a sex-based difference in survival (102). A meta-analysis with 86,800 patients with 
lung cancer found that being a woman was associated with approximately 20% lower hazard 
of death compared to men (HR = 0.78, 95% CI: 0.75–0.81) (107). A study from the USA 
reported longer survival associated with being a woman among untreated patients (HR = 
0.85, 95% CI: 0.77–0.93), suggesting that lung cancer has a different natural history in 
women compared to men (108). The reason for the observed sex-based difference in survival 
is not fully understood, and different explanations are often proposed and have been 
discussed in the literature, for example, smoking history, the influence of sex hormones, and 
differences in tumour biology (11, 108).  
Age 
The reported results on age as a prognostic factor for lung cancer survival are conflicting. A 
review published in 2014 which included 39 studies that assessed the prognostic impact of 
age reported that only four of the studies had estimated an association with age (102). Three 
of these reported longer survival for older patients, while one reported longer survival for 
younger patients.  
Socioeconomic status 
The positive association between socioeconomic status and survival in patients with lung 
cancer (i.e. higher survival for those with higher socioeconomic status) is observed in 
different settings, including countries with universal healthcare systems (109). A Swedish 
study found that a high educational level was associated with longer survival in patients with 
NSCLC in stages I–II compared to those with a low educational level (HR = 0.86, 95% CI: 
0.77–0.92) (113). An association was not found among patients with more advanced stages 
(stage IIIA: HR = 1.12, 95% CI: 0.99–1.26; stages IIIB–IV: HR = 0.99, 95% CI: 0.95–1.03) 
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(113). Similar results of an association between socioeconomic group and survival for 
patients with early-stage lung cancer have been reported from England (114). 
Smoking 
The prognostic impact of smoking is well-established, and being an ever-smoker has 
consistently been associated with shorter survival (102, 110-112). A review with six studies 
which assessed the difference in survival by smoking status reported that all six studies 
estimated longer survival associated with a shorter or no history of smoking (102). It is 
estimated that approximately 50% of patients who smoked at diagnosis continued to smoke 
after diagnosis (115). One hypothesised reason for the survival difference is that tobacco 
smoke alters the metabolic rate of several chemotherapies by inducing enzymes in the 
cytochrome P450 system, resulting in lower plasma levels of chemotherapies (116, 117). 
Other potential explanations discussed in the literature are the impaired wound healing 
caused by smoking, smoking-associated oxidative stress, immune suppression resulting in 
cancer progression, nicotine-induced angiogenesis that stimulates and facilitate tumour 
growth, and post-diagnosis development of smoking-related comorbidity increasing the risk 






The overall objectives of the thesis are to investigate possible factors associated with a 
subsequent diagnosis of lung cancer and survival after a diagnosis of lung cancer using 
routinely collected healthcare data from a universal healthcare setting. 
The specific objectives of each of the four included studies are: 
I. To estimate the association between filling a prescription of antimuscarinic 
medications used to treat overactive bladder (OAB) and a subsequent diagnosis of 
lung cancer. 
II. To compare clinical characteristics, demographics and survival in patients with 
NSCLC by smoking status at diagnosis. 
III. To examine patterns of recent fillings of prescriptions of antibiotics recommended for 
the treatment of pneumonia as an indicator of early symptoms of lung cancer. 





3 MATERIALS AND METHODS 
3.1 DATA SOURCES 
For study I, we acquired data from the Swedish Cancer Register (SCR), the National Patient 
Register (NPR), the Prescribed Drug Register (PDR), the Cause of Death Register (CDR), 
and the Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA). In studies II–IV, the data was acquired from the Lung Cancer DataBase Sweden 
(LCBaSe). Record linkage between the registers was made feasible using the personal 
identity number, a unique personal identifier given to all permanent residents of Sweden, 
which is included in all of the registers (120). The registers and databases used as data 
sources in this thesis are described in detail below. 
LCBaSe 
The LCBaSe is a research database generated by record linkage between the Swedish 
National Lung Cancer Register (NLCR) and several other population-based registers in 
Sweden, namely the SCR, the CDR, the NPR, the PDR, the Multi-generation Register 
(MGR), the LISA database, and the Swedish Population Register (Figure 2). Each patient 
with lung cancer in the LCBaSe has been individually matched with up to five individuals 
free of lung cancer from the general Swedish population. The matching was based on year of 
birth, sex, and place of residence at the time of the diagnosis of lung cancer. In this thesis, we 
used data in the LCBaSe from the NLCR, the SCR, the CDR, the NPR, the PDR, the LISA 
database, and the Swedish Population Register; these registers are described in detail below 
(121-127).  
 





The NLCR, a nationwide population-based register established in 2002, aims to include all 
newly diagnosed patients with lung cancer (International Classification of Diseases [ICD] 
seventh edition [ICD-7] code: 1621 or ICD for oncology third edition [ICD-O-3] code: C34) 
in Sweden (121, 128, 129). Before 2002, the register was a regional population-based register 
in the healthcare region of Uppsala-Örebro (approximately two million inhabitants, 20% of 
the entire Swedish population). Compared to the SCR, where reporting is mandated by law, 
the NLCR covers more than 95% of newly diagnosed patients with lung cancer in Sweden. 
The NLCR records individual-level information on, for example, sex, age, smoking status, 
histopathology, cancer stage, PS, EGFR mutation status (2010 onwards), diagnostic 
procedures, basis of diagnosis, and planned primary treatment. The NLCR does not include 
tumours discovered at autopsy, that is, there is no inclusion of death certificate only (DCO) 
cases. The NLCR is held by the Regional Cancer Centre (RCC) in the healthcare region of 
Uppsala-Örebro. 
SCR 
The SCR was established in 1958 and records individual-level data (e.g. site of cancer, 
histopathology, date of diagnosis and basis of diagnosis) on all newly diagnosed malignant 
tumours in Sweden (122). The cancers are recorded using the latest versions of the ICD codes 
(ICD-7 [1952–1968], ICD-8 [1969–1986], ICD–9 [1987–1996] and ICD-10 [1997 onwards]) 
or ICD-O codes (ICD-O-2 [1993–2004] and ICD-O-3 [2005 onwards]), and the historical 
seventh edition (ICD-7) is always included (130). Reporting to the register is mandated by 
law. In 1998, it was estimated that the underreporting to the register was approximately 4%, 
with higher underreporting in the elderly, which is similar to other population-based cancer 
registers in Europe (131-134). The six RCCs in Sweden perform the registration of incident 
cancers and annually send their data to the National Board of Health and Welfare (NBHW), 
where the SCR is held. In this thesis, we did not include data on DCO cases from the SCR. 
CDR 
The CDR is held at the NBHW and was established in 1961 (123, 135). The register includes 
individual-level information, from death certificates, on the underlying and contributing 
causes of death (using the latest version of ICD codes) and the date of death for all deaths 
occurring among Swedish residents each year. Stillbirths are not included in the CDR. Less 
than 1% of recorded deaths in the CDR are missing an underlying cause of death (coded as 
death certificate not received). The overall agreement between the cause of death recorded in 
the register and relevant information from medical records has been estimated at 
approximately 80%, and 90% for malignancies, with higher agreement in younger individuals 
(136). The underlying cause of death is defined in ICD-10 as ‘(a) the disease or injury which 
initiated the train of morbid events leading directly to death, or (b) the circumstances of the 
accident or violence which produced the fatal injury’ (137). In the presence of more than one 
cause of death recorded by the physician on the death certificate, the process to assign an 
underlying cause is complex. In brief, the physician has to specify the conditions that played 
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a role in the death and then separate the conditions that directly led to the death from other 
significant conditions that contributed to the death. 
NPR 
The NPR is held by the NBHW and was created in 1964 as the Hospital Discharge Register 
that collected individual-level data on somatic inpatient care, and since 1973, psychiatric 
inpatient care has been included (124). Due to regional discrepancies in recording practices, 
national coverage was not achieved until 1987. Since 2001, the register has included 
information on outpatient visits, with increasing coverage during the first few years. Main 
and secondary diagnoses are recorded using the latest version of ICD codes. Information on 
diagnoses given in primary care is not included in the NPR. It is estimated that the national 
completeness for inpatient care is approximately 99% for somatic and psychiatric discharges, 
and the validity of the recorded information is approximately 90% (138). However, the 
completeness is lower (80%) for outpatient care.  
PDR 
Since July 2005, the PDR has recorded individual-level information on all filled prescriptions 
from community pharmacies, for example, the active substance (coded according to the 
anatomical therapeutic chemical [ATC] codes), amount (e.g. the number of tablets or defined 
daily dose [DDD]), date of prescription, and date when the prescription was filled (125, 139). 
Initially, information on filled prescriptions is reported by the community pharmacies to the 
Swedish eHealth Agency and is subsequently transferred to the NBHW, where the PDR is 
created and held. The completeness and validity of the data are virtually 100%, mainly due to 
the fact that the registration is almost exclusively automatic. The PDR does not include data 
on over-the-counter medications or medications used in hospitals, nursing homes or prisons. 
LISA database 
The sociodemographic information in this thesis was retrieved from the LISA database (126). 
The database integrates existing data from registers on, for example, education and income. 
Currently, the LISA database holds information on all permanent residents in Sweden aged 
16 years and over for every year since 1990.  
Swedish Population Register 
The Swedish Population Register covers all permanent residents in Sweden and is held by the 
Swedish Tax Agency (127). The register contains information on, for example, date of birth, 
death and migration.   
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3.2 MAIN STATISTICAL METHODS 
3.2.1 Survival analysis 
Survival analysis refers to the area of analysis of time-to-event data (140). Subjects are 
followed over time from a pre-specified time of origin to the occurrence of an event of 
interest or censoring. Censoring occurs when the event status of a subject is unknown. The 
studies in this thesis only consider right censoring. Right censoring is that up until a specific 
time point no event has been registered due to, for example, migration or administrative 
censoring (i.e. no more data is available). After that time point, although we know that the 
event could occur, we are not able to determine if or when. Non-informative censoring is 
assumed in all studies included in this thesis. Non-informative censoring means that the time 
of censoring is independent of the event time, namely the distribution of censoring times 
provides no information on the distribution of event times. This thesis considers two types of 
events for time-to-event data: cancer as an outcome (i.e. cancer incidence) and death (i.e. 
mortality).  
The survival function gives the probability of having a survival time, T, after time t: 
𝑆 (𝑡) = 𝑃(𝑇 > 𝑡), 0 < 𝑡 <  ∞  
The survival function can only take a value between 0 and 1 (0% and 100%) and cannot 
increase by time (i.e. non-increasing by nature). The hazard function describes the 
instantaneous rate at time t of experiencing the event of interest, conditional on having 
survived until time t: 
𝜆(𝑡) = lim
Δt→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 +  Δ𝑡|𝑇 ≥ 𝑡)
Δ𝑡
 






The Kaplan–Meier method is a non-parametric method used to estimate survival curves, 
namely one is not assuming anything regarding the shape of the underlying hazard function 







where nj is the number of individuals at risk at time 𝑡𝑗 and 𝑑𝑗 is the number of failures or 
events (e.g. diagnoses of cancer or deaths) at time 𝑡𝑗. The survival probability is estimated at 
every time an event occurs and is calculated as the number of individuals surviving that time 
interval divided by the number of individuals at risk at the start of that time interval. 
Individuals who have been censored (e.g. emigrated) before that time interval are not 
considered to be at risk. The total probability of surviving until a specific time is calculated 
by multiplying all the probabilities of survival preceding that specific time interval. 
In RCTs, the Kaplan–Meier method is the main method used to analyse and present time-to-
event data since the randomisation makes it reasonable to assume that the populations are the 
same apart from the exposure (142). However, in observational studies, to control for 
potential confounders, it is often necessary to adjust the analyses. 
Application in study II 
The Kaplan–Meier method was used in study II to estimate unadjusted survival curves among 
patients diagnosed with lung cancer. This was carried out by smoking status overall and in 
subgroups of cancer stage at diagnosis.  
Cox proportional hazard model 
Currently, the Cox proportional hazard model is the most common method used to analyse 
time-to-event data in observational studies (140, 143). The Cox model is formulated as: 
 
𝜆(𝑡) = 𝜆0(𝑡) ∗ exp (𝛽1𝑥1 + ⋯ +  𝛽𝑛𝑥𝑛) 
where λ(t) is the hazard function; λ0(t) is the baseline hazard function, namely when all 
covariates are at their pre-specified baseline levels; xn are the covariates; and βn are their 
estimated coefficients. In the model, only the βs are estimated, while the λ0(t) is not 
estimated; therefore, the Cox model is a semi-parametric model, namely one can estimate the 
relative effect (i.e. HR) but not the absolute effect. The basic assumptions of the Cox model 
are that the hazards for the compared populations are proportional over time and that the 
censoring is non-informative (i.e. censoring times are unrelated to the event times). In this 
thesis, the proportional hazards assumption was tested by the introduction of an interaction 
term between the exposure and the follow-up time (underlying time scale) or with scaled 




Application in studies I and II 
In study I, a Cox proportional hazard model was used to study the incidence of lung cancer 
by exposure to antimuscarinic medications. In this case, the hazard represents the incidence 
rate and the HR is the incidence rate ratio between exposed and unexposed individuals.  
In study II, a Cox proportional hazard model was used to study mortality among patients with 
lung cancer in relation to their smoking status at diagnosis. When studying mortality, the 
hazard represents the mortality rate and the HR is to be interpreted as the mortality rate ratio 
between the groups.  
Relative survival 
Relative survival is an estimation of the net survival (i.e. probability of survival in the 
absence of other causes of death) and is defined as the ratio of the all-cause survival of the 





where 𝑆(𝑡) is the overall survival in the patient cohort and 𝑆∗(𝑡) is the expected survival at 
time 𝑡 after the diagnosis. The expected survival is calculated for a whole population, derived 
from life tables, which are often used as a proxy for the survival that the diseased would have 
experienced had they not been diseased. In this thesis, this is the survival for patients with 
lung cancer had they been free of lung cancer. The main advantage of using relative survival 
instead of cause-specific survival is that the validity of the estimates does not rely on the 
validity of the reported cause of death.  
Application in study IV 
In study IV, relative survival and temporal trends in relative survival for patients with lung 
cancer were estimated. This was carried out overall and in different subgroups defined by 




3.2.2 Logistic regression 
Logistic regression models are common and useful in epidemiological research when the 
outcome variable is binary (e.g. 0/1, no/yes, no diagnosis/diagnosis). Logistic regression is 
used to model the probability of a certain event given a set of covariates. For a binary 




= 𝑒𝑥𝑝 ( 𝛽0 +  𝛽1𝑥1 + ⋯ +  𝛽𝑛𝑥𝑛)  
where 𝑝 is the probability of the outcome, 𝑥𝑛are the covariates, and 𝛽𝑛 are their estimated 
coefficients. 
Application in study III 
In study III, a logistic regression model was used to estimate the association between a 




4 SUMMARY OF STUDIES 
4.1 STUDY I 
Background: Preclinical studies have found that antimuscarinic substances inhibit cell 
proliferation in lung cancer. 
Study population: Individuals with a first-time filled prescription of an antimuscarinic 
medication used to treat OAB between 2006 and 2012 (index date) as recorded in the PDR 
(exposed). Each exposed individual was matched (based on year of birth, sex, and place of 
residence at the index date) with unexposed individuals (i.e. not exposed before the index 
date) from the general population.  
Study design: Population-based cohort study. 
Setting: Sweden. 
Exposure: Antimuscarinic medications indicated for the treatment of OAB. 
Main outcome: A diagnosis of lung cancer (ICD-7:1621, 163; ICD-O-3: C34, C39). Colon 
cancer was also included in the study but will not be discussed in this thesis. 
Statistical analyses: A Cox proportional hazard model was used to estimate HR for the 
association between exposure and a diagnosis of lung cancer. The unexposed individuals 
were the reference group. Follow-up started on the index date and ended on the date of one of 
the following events: a diagnosis of lung cancer (i.e. event of interest), death, emigration or 
administrative censoring (31 December 2013), whichever occurred first. The proportional 
hazard assumption was tested by introducing an interaction term between exposure and 
follow-up time. If the proportional hazard assumption was not met, HRs were estimated 
separately for different intervals of the follow-up time. The data was analysed using an 
intention-to-treat approach, namely no consideration was taken of change in exposure status 
after the index date.  
Results: The study included 164,000 individuals classified as exposed to antimuscarinic 
medications and 1,446,472 unexposed individuals. The estimated incidence rate difference 
was −44.9 (95% CI: −53.3, −36.5) per 100,000 person-years. The negative incidence rate 
difference indicates that there is a lower incidence rate for the exposed individuals compared 
to the unexposed individuals. Also, the HR below one from the Cox model indicates that 
being exposed was associated with lower incidence of lung cancer (Table 5). The magnitude 
of the HR for the inverse association became more pronounced with longer time since the 
index date and an indication of a pronounced association for the highest group of cumulative 
DDD (≥365 DDDs). However, we did not find a difference in the effect size by sex. The 
point estimate for the HR became slightly more pronounced when applying a lag time (i.e. no 




Table 5. HR and 95% CI for the association between exposure to antimuscarinic medications and lung cancer, 
Swedish Cancer Register and the Prescribed Drug Register, 2006–2012. Time since index date (i.e. date of 
incidence prescription of a study medication for the exposed individuals and the corresponding date for the 
matched unexposed individuals) was used as the underlying time scale  
 
Group  n1 HR (95% CI)2  
Overall     
Unexposed  8,394 1 (ref) 
Exposed  659   
 <1 year 234 0.86 (0.75−0.98) 
 1–4 years 347 0.63 (0.56–0.70) 
 ≥4 years 78 0.43 (0.34–0.55) 




   
3,823 1 (ref) 
Exposed  323   
 <1 year 106 0.81 (0.66–0.99) 
 1–4 years 179 0.64 (0.54–0.74) 
 ≥4 years 38 0.37 (0.26–0.51) 




   
4,571 1 (ref) 
Exposed  336   
 <1 year 128 0.90 (0.75–1.08) 
 1–4 years 168 0.62 (0.53–0.72) 
 ≥4 years 40 0.51 (0.37–0.70) 
Cumulative DDD3     
 ≤90 340 1 (ref) 
 91–180 103 0.96 (0.76–1.20) 
 181–364 83 1.01 (0.79–1.29) 
 ≥365 133 0.82 (0.67–1.00) 
Abbreviations: Hazard ratio (HR), Confidence interval (CI), Defined daily dose (DDD). 
 
1 Number of individuals with an event of interest, i.e. a diagnosis of lung cancer. 
2 Adjusted for year of birth, sex, place of residence, income, educational level, and a proxy variable for smoking (i.e. a diagnosis of chronic obstructive 
pulmonary disease or a filled prescription for a smoking cessation medication within five years prior to the index date, i.e. date of incidence 
prescription of a study medication for the exposed individuals and the corresponding date for the matched unexposed individuals). 





Table 6. HR and 95% CI for the association between exposure to antimuscarinic medications and lung cancer, 
Swedish Cancer Register and the Prescribed Drug Register, 2006–2012, when applying a lag time period 
directly after index date (i.e. no events of interest are considered within this time period). Time since end of lag 
time (i.e. six and 12 months respectively after index date, i.e. date of incidence prescription of a study 
medication for the exposed individuals and the corresponding date for the matched unexposed individuals) 
was used as the underlying time scale  
 
Group  n1 HR (95% CI)2  
6 months lag     
Unexposed  7,226 1 (ref) 
Exposed  530   
 <1 year 176 0.70 (0.60–0.82) 
 1–4 years 311 0.64 (0.57–0.72) 
 ≥4 years 43 0.33 (0.24–0.45) 
12 months lag     
Unexposed  6,107 1 (ref) 
Exposed  425   
 <1 year 139 0.62 (0.52–0.74) 
 1–4 years 258 0.61 (0.54–0.70) 
 ≥4 years 28 0.30 (0.21–0.45) 
Abbreviations: Hazard ratio (HR), Confidence interval (CI). 
 
1 Number of individuals with an event of interest, i.e. a diagnosis of lung cancer. 
2 Adjusted for year of birth, sex, place of residence, income, educational level, and a proxy variable for smoking (i.e. a diagnosis of chronic obstructive 
pulmonary disease or a filled prescription for a smoking cessation medication within five years prior to the index date, i.e. date of incidence 
prescription of a study medication for the exposed individuals and the corresponding date for the matched unexposed individuals). 
Discussion: Our finding of an inverse association between exposure to antimuscarinic 
medications and incidence of lung cancer was in accordance with results of a study 
investigating the same association using data from Denmark (148). The more pronounced 
inverse association with longer follow-up time could indicate that it takes time from the start 
of the exposure until we can see a biological effect of the exposure on cancer incidence. The 
indication of a pronounced magnitude of the inverse association for those in the highest group 
of cumulative DDD (≥365 DDDs) compared to the lower groups is an indication of a dose–
response relationship between exposure and outcome. In line with the study from Denmark, 
we did not find any evidence in support of a sex-based difference in the effect of 
antimuscarinic medications on lung cancer incidence (148). 
Conclusion: We found an inverse association between exposure to antimuscarinic 
medications, used in the treatment of OAB, and a diagnosis of lung cancer. The magnitude of 
the effect size became more pronounced with longer time since the start of treatment and with 
a higher cumulative dose. These findings generate hypotheses regarding the prevention of 




4.2 STUDY II 
Background: Previous epidemiological studies on differences in patient characteristics and 
survival by smoking status in lung cancer have been limited by selective data and small study 
populations. 
Study population: Individuals with a first-time diagnosis of NSCLC between 2002 and 2016 
as recorded in the NLCR.  
Study design: Population-based cohort study. 
Setting: Sweden. 
Exposure: The patients were classified based on self-reported smoking status at diagnosis: 
current smokers (smoked at diagnosis or stopped <1 year before), former smokers (stopped 
≥1 year before diagnosis), and never-smokers (never smoked on a regular basis). 
Main outcome: Lung cancer-specific mortality (ICD-7: 1621, ICD-10: C34). 
Statistical analyses: The Kaplan–Meier method was used to estimate unadjusted lung 
cancer-specific survival curves. A Cox proportional hazard model was used to estimate HR 
for lung cancer-specific mortality, with the current smokers as the reference group. Follow-up 
started on the date of diagnosis and ended on the date of one of the following events: death 
due to lung cancer (i.e. event of interest), death due to other causes, emigration or 
administrative censoring (31 December 2016), whichever occurred first. The proportional 
hazard assumption was tested using the scaled Schoenfeld residuals. If the proportional 
hazard assumption was not fulfilled, HRs were estimated in separate intervals of the follow-
up time by the introduction of an interaction term between the smoking status and the follow-
up time. 
Results: We included 41,262 patients with NSCLC, of whom 43% were current smokers, 
44% former smokers, 11% never-smokers, and data on smoking history was not available for 
2%. Compared to current smokers, a higher median age at diagnosis and a larger proportion 
of patients aged ≤50 years were observed for never-smokers. Moreover, overrepresentation of 
women, adenocarcinoma, EGFR mutation, and stage IV was found among never-smokers. In 
addition, we found that being a never-smoker was associated with longer survival in the first 
years after the diagnosis of lung cancer (Figure 3, Table 7). The estimated longer survival 





Figure 3. Lung cancer-specific survival by smoking status at diagnosis among patients diagnosed with non-small cell 
lung cancer, Lung Cancer DataBase Sweden, 2002–2016. Current smokers (blue), former smokers (red) and never-
smokers (purple). Smoking status was based on self-reported information at diagnosis: current smokers (smoked at diagnosis 





Table 7. HR and 95% CI for the association between smoking status1 at diagnosis and lung cancer-specific mortality 
among patients diagnosed with non-small cell lung cancer, Lung Cancer DataBase Sweden, 2002–2016. Time since 
diagnosis was used as the underlying time scale.  
   Stage at diagnosis 
   I–II  III IV 
   HR
2 (95% CI)  HR2 (95% CI)  HR2 (95% CI)  
Overall     
 Current smokers 1 (ref)   (ref)  1 (ref)  
 Former smokers 0.95 (0.88–1.01)  0.94 (0.89–0.99)  0.90 (0.87–0.93)  
 Never-smokers 0.81 (0.71–0.93)        
  ≤0.5 years since diagnosis    0.78 (0.67–0.90)  0.65 (0.61–0.70)  
  >0.5, ≤1 years since diagnosis    0.70 (0.59–0.83)  0.69 (0.62–0.76)  
  >1, ≤2 years since diagnosis    0.88 (0.75–1.05)  0.63 (0.56–0.71)  
  >2 years since diagnosis    1.01 (0.83–1.22)  0.91 (0.77–1.06)  
Men      
 Current smokers 1 (ref)  1 (ref)  1 (ref)  
 Former smokers 0.94 (0.86–1.04)  0.97 (0.91–1.04)  0.87 (0.83–0.91)  
 Never-smokers 0.80 (0.64–1.01)        
  ≤0.5 years since diagnosis    0.69 (0.53–0.90)  0.65 (0.58–0.72)  
  >0.5, ≤1 years since diagnosis    0.56 (0.41–0.77)  0.59 (0.50–0.70)  
  >1, ≤2 years since diagnosis    0.86 (0.65–1.12)  0.55 (0.45–0.67)  
  >2 years since diagnosis    1.16 (0.85–1.59)  1.02 (0.79–1.32)  
Women     
 Current smokers 1 (ref)  1 (ref)  1 (ref)  
 Former smokers 0.94 (0.84–1.05)  0.88 (0.82–0.96)  0.93 (0.88–0.98)  
 Never-smokers 0.84 (0.71–0.99)        
  ≤0.5 years since diagnosis    0.83 (0.69–1.01)  0.64 (0.58–0.70)  
  >0.5, ≤1 years since diagnosis    0.78 (0.63–0.97)  0.79 (0.70–0.90)  
  >1, ≤2 years since diagnosis    0.91 (0.73–1.12)  0.71 (0.61–0.82)  
  >2 years since diagnosis    0.92 (0.72–1.18)  0.87 (0.71–1.07)  
Abbreviations: Hazard ratio (HR), Confidence interval (CI). 
 
1 Smoking status was based on self-reported information at diagnosis: current smokers (smoked at diagnosis or stopped <1 year before), former smokers (stopped ≥1 year 
before diagnosis), and never-smokers (never smoked on a regular basis). 
2 Adjusted for sex (in the overall analysis), age, histopathology, World Health Organization performance status, primary planned treatment, Charlson Comorbidity Index, 
and educational level. 
Discussion: The findings regarding higher median age and overrepresentation of women, 
adenocarcinoma, and patients with EGFR mutation among never-smokers confirm those of 
previous studies and corroborate the suggestion that lung cancer in never-smokers may be 
considered a different disease compared to smoking-associated lung cancer (9, 10, 110-112, 
149-165). However, the higher proportion of younger patients (≤50 years) among never-
smokers compared to smokers has not been described frequently and is an indication of a 
stronger hereditary effect for lung cancer in never-smokers compared to lung cancer in 
smokers (55, 166). Moreover, we found that stage IV cancer was more common in never-
smokers; however, whether smoking status is associated with cancer stage remains unclear, 
with conflicting results in the available literature (112, 152, 153, 155, 156, 158-160). A 
systematic review published in 2019 that investigated barriers of early diagnosis of lung 
cancer identified low awareness of lung cancer symptoms among both physicians and 
patients as a barrier (167). It is reasonable to consider the awareness of lung cancer as a 
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possible reason for presenting symptoms to be lower among never-smokers, and that this may 
explain the higher proportion of patients with stage IV cancer.  
Our finding of longer survival for never-smokers compared to smokers is in accordance with 
those of other studies (102, 110-112). It has been suggested that tobacco smoke alters the 
metabolic rate of several chemotherapies by inducing enzymes in the cytochrome P450 
system, resulting in lower plasma levels of cytostatic agents and subsequently leading to 
lower survival for smokers compared to never-smokers (116, 117). Other suggested reasons 
for the difference in survival are impaired wound healing caused by smoking, smoking-
associated oxidative stress, immune suppression resulting in cancer progression, nicotine-
induced angiogenesis that stimulates and facilitates tumour growth, and post-diagnosis 
development of smoking-related comorbidities increasing the risk of death (115, 118, 119).  
Conclusion: The observed differences in age and sex distribution, histopathology, EGFR 
mutation, cancer stage, and survival between smokers and never-smokers in this study 
emphasise the need for an improved understanding of non-tobacco-associated lung cancer 




4.3 STUDY III 
Background: Little is known about patterns of pre-diagnostic use of antibiotics as an 
indicator of early symptoms of lung cancer.  
Study population: Individuals with a first-time diagnosis of lung cancer between 2009 and 
2016 as recorded in the NLCR (cases). Each case was individually matched with individuals 
free of lung cancer from the general population (controls) using a risk set sampling approach 
(i.e. concurrent sampling) at the date of the diagnosis for the cases (index date). The matching 
factors were year of birth, sex, and place of residence at the index date. 
Study design: Population-based case-control study. 
Setting: Sweden. 
Exposure: Recent history (i.e. within three years prior to the index date) of filled 
prescriptions of antibiotics recommended for the treatment of pneumonia. 
Main outcomes: A diagnosis of lung cancer (ICD-7: 1621, ICD-O-3: C34).  
Statistical analyses: A logistic regression model was used to estimate the odds ratio (OR) for 
the association between a diagnosis of lung cancer and a history of recent pre-diagnostic 
filled prescriptions of antibiotics recommended for the treatment of pneumonia.  
Results: A total of 27,017 cases and 129,355 controls were included. Of the cases, 50% had 
filled at least one prescription, 25% had a history of repeated fillings, and 7% had four or 
more fillings, with a maximum of 63 treatment cycles. The corresponding proportions for the 
controls were 33%, 13% and 4% respectively, with a maximum of 78 treatment cycles. 
Compared to the individuals free of lung cancer, the likelihood of a recent history of at least 
one filled prescription was higher for the patients with lung cancer, NSCLC overall (OR: 
1.83, 95% CI: 1.77–1.88), squamous cell carcinoma (OR: 2.18, 95% CI: 2.05–2.32), 
adenocarcinoma (OR: 1.70, 95% CI: 1.64–1.77), and SCLC (OR: 1.92, 95% CI: 1.78–2.06). 
The magnitude of the effect size became more pronounced with an increasing number of 
filled prescriptions (Figure 4) and with proximity to the diagnosis (Figure 5). However, the 
magnitude of the effect size did not differ by sex or educational level and became attenuated 





Figure 4. Adjusted odds ratios (solid line) and 95% confidence intervals (shaded area) for the association between a 
diagnosis of lung cancer and the number of recently filled prescriptions of antibiotics recommended for the treatment 
of pneumonia, Lung Cancer DataBase Sweden, 2009–2016. The odds ratios were adjusted for year of birth, sex, place of 
residence, educational level, previous diagnosis of chronic obstructive pulmonary disease, previous use of antibiotics 
recommended for the treatment of pneumonia, and history of any cancer. The observation period was three years before 
diagnosis of lung cancer 
 
 
Figure 5. Adjusted odds ratios for the association between a diagnosis of lung cancer and a history of at least one filled 
prescription of antibiotics recommended for the treatment of pneumonia in different intervals of the period prior to 
the date of lung cancer diagnosis, Lung Cancer DataBase Sweden, 2009–2016. The odds ratios were adjusted for year of 
birth, sex, place of residence, educational level, previous diagnosis of chronic obstructive pulmonary disease, previous use of 





Table 8. OR and 95% CI for the association between a diagnosis of lung cancer and a recent history of at least 
one filled prescription of antibiotics recommended for the treatment of pneumonia, Lung Cancer DataBase 
Sweden, 2009–2016 
  Exposed individuals1  OR (95% CI) 
 Cases Controls Unadjusted Adjusted2 
NSCLC, overall      
Sex               
  Men 5,553 17,382 2.00 (1.92–2.08) 1.80 (1.73–1.88) 
  Women 5,949 19,090 2.08 (2.00–2.17) 1.86 (1.78–1.94) 
Age at diagnosis (years)        
 <50 257 798 2.26 (1.90–2.71) 2.20 (1.84–2.63) 
 50–59 1,136 3,493 2.31 (2.11–2.52) 2.15 (1.97–2.35) 
 60–69 4,120 13,131 2.08 (1.99–2.18) 1.91 (1.82–2.00) 
 70–79 4,277 13,661 1.96 (1.88–2.05) 1.72 (1.64–1.80) 
 ≥80 1,712 5,389 1.94 (1.81–2.08) 1.68 (1.56–1.81) 
Educational level3        
 Low 4,447 11,473 2.06 (1.98–2.16) 1.77 (1.69–1.86) 
 Middle 4,941 14,800 2.12 (2.03–2.21) 1.89 (1.81–1.97) 
 High 1,970 9,814 1.93 (1.81–2.06) 1.81 (1.69–1.93) 
 Missing 144 385 1.90 (1.51–2.39) 1.68 (1.33–2.13) 
Squamous cell carcinoma       
Sex               
  Men 1,747 4,977 2.46 (2.31–2.63) 2.13 (2.00–2.28) 
  Women 1,219 3,441 2.65 (2.48–2.84) 2.26 (2.10–2.43) 
Age at diagnosis (years)        
 <50 26 67 2.97 (2.46–3.59) 2.76 (2.28–3.34) 
 50–59 250 599 2.94 (2.65–3.26) 2.63 (2.37–2.93) 
 60–69 957 2,696 2.64 (2.46–2.84) 2.33 (2.16–2.51) 
 70–79 1,225 3,522 2.45 (2.28–2.62) 2.07 (1.93–2.22) 
 ≥80 508 1,534 2.40 (2.20–2.61) 2.00 (1.84–2.19) 
Educational level3           
 Low 1,246 2,906 2.55 (2.38–2.73) 2.11 (1.97–2.27) 
 Middle 1,264 3,300 2.64 (2.46–2.82) 2.26 (2.11–2.43) 
 High 413 2,118 2.42 (2.22–2.63) 2.17 (1.99–2.37) 
 Missing 43 94 2.34 (1.85–2.97) 2.00 (1.57–2.55) 
Adenocarcinoma       
Sex               
  Men 3,045 9,980 1.80 (1.72–1.88) 1.65 (1.57–1.73) 
  Women 3,980 13,319 1.94 (1.85–2.02) 1.75 (1.67–1.83) 
Age at diagnosis (years)             
 <50 198 629 2.16 (1.81–2.59) 2.11 (1.76–2.53) 
 50–59 747 2,455 2.14 (1.96–2.34) 2.01 (1.84–2.20) 
 60–69 2,667 8,815 1.92 (1.83–2.02) 1.78 (1.69–1.88) 
 70–79 2,482 8,342 1.78 (1.69–1.87) 1.58 (1.50–1.67) 
 ≥80 931 3,058 1.74 (1.62–1.88) 1.53 (1.42–1.65) 
Educational level3             
 Low 2,582 7,023 1.89 (1.79–1.98) 1.64 (1.56–1.73) 
 Middle 3,024 9,546 1.95 (1.86–2.05) 1.76 (1.68–1.85) 
 High 1,341 6,495 1.79 (1.67–1.91) 1.69 (1.58–1.81) 
 Missing 78 235 1.73 (1.37–2.18) 1.56 (1.23–1.98) 
SCLC       
Sex               
  Men 887 2,746 2.11 (1.96–2.28) 1.89 (1.74–2.04) 
  Women 1,095 3,350 2.21 (2.05–2.38) 1.95 (1.80–2.10) 
Age at diagnosis (years)             
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Table 8. OR and 95% CI for the association between a diagnosis of lung cancer and a recent history of at least 
one filled prescription of antibiotics recommended for the treatment of pneumonia, Lung Cancer DataBase 
Sweden, 2009–2016 
  Exposed individuals1  OR (95% CI) 
 Cases Controls Unadjusted Adjusted2 
 <50 46 120 2.40 (1.98–2.89) 2.30 (1.90–2.79) 
 50–59 223 636 2.43 (2.19–2.72) 2.25 (2.01–2.51) 
 60–69 727 2,331 2.20 (2.03–2.39) 1.99 (1.84–2.16) 
 70–79 757 2,322 2.07 (1.92–2.24) 1.80 (1.66–1.95) 
 ≥80 229 687 2.05 (1.86–2.26) 1.76 (1.59–1.94) 
Educational level3             
 Low 818 1,850 2.20 (2.03–2.38) 1.86 (1.72–2.02) 
 Middle 864 2,521 2.25 (2.09–2.44) 1.98 (1.83–2.15) 
 High 277 1,680 2.05 (1.87–2.25) 1.89 (1.72–2.08) 
 Missing 23 45 2.01 (1.59–2.56) 1.76 (1.38–2.26) 
Abbreviations: Odds ratio (OR), Confidence interval (CI), Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC).  
 
1 Individuals with at least one filled prescription of antibiotics recommended for the treatment of pneumonia as recorded in the Prescribed Drug Register 
within three years before the index date (i.e. the date of lung cancer diagnosis and the corresponding date for the matched individuals free of lung cancer).  
2 Adjusted for year of birth, sex, place of residence, educational level, previous diagnosis of chronic obstructive pulmonary disease, previous use of 
antibiotics recommended for the treatment of pneumonia, and history of any cancer.  
3 Highest attained educational level the year before the index date categorised by years of formal education: ≤9 (low, mandatory), 10–12 (middle, upper 
secondary), and ≥13 (high, post-upper secondary). 
 
For the association between a diagnosis of lung cancer and a recent pre-diagnostic history of 
repeated fillings, we found no trend in the magnitude of the effect size by stage (Table 9). 
However, the results indicate that the magnitude of the effect size was slightly more 
pronounced for patients with stage III disease compared to stage IV disease. In separate 





Table 9. OR and 95% CI for the association between a diagnosis of lung cancer and a recent history of repeated 
fillings (≥2 fillings) of antibiotics recommended for the treatment of pneumonia, Lung Cancer DataBase Sweden, 
2009–2016 
  Exposed individuals1  OR (95% CI) 
 Cases Controls Unadjusted Adjusted2 
NSCLC, overall      
Overall  5,746 14,489 2.57 (2.48–2.67) 2.18 (2.10–2.27) 
Stage at diagnosis3        
 I–II 1,576 3,660 2.94 (2.74–3.17) 2.28 (2.11–2.47) 
 III 1,320 2,996 3.04 (2.81–3.30) 2.54 (2.33–2.77) 
 IV 2,796 7,692 2.25 (2.14–2.37) 2.02 (1.91–2.13) 
 Missing 54 141 2.45 (1.69–3.57) 2.10 (1.39–3.18) 
T-descriptor3        
  1 1,311 3,131 2.81 (2.60–3.03) 2.29 (2.12–2.48) 
  2 1,594 4,169 2.41 (2.26–2.58) 2.03 (1.89–2.17) 
 3 950 2,337 2.63 (2.42–2.87) 2.17 (1.99–2.38) 
 4 1,794 4,589 2.55 (2.40–2.71) 2.17 (2.04–2.32) 
 Missing 97 263 2.29 (1.79–2.91) 1.87 (1.45–2.40) 
N-descriptor3        
  0 2,272 5,659 2.53 (2.39–2.68) 2.08 (1.96–2.21) 
  1 419 1,156 2.34 (2.06–2.66) 1.93 (1.69–2.20) 
  2 1,659 4,190 2.66 (2.50–2.84) 2.25 (2.10–2.40) 
  3 1,251 3,080 2.67 (2.48–2.87) 2.29 (2.13–2.47) 
  Missing 145 404 2.15 (1.75–2.63) 1.73 (1.40–2.13) 
Squamous cell carcinoma       
Overall  15,877 3,291 3.48 (3.23–3.75) 2.75 (2.53–2.99) 
Stage at diagnosis3        
 I–II 480 962 3.61 (3.14–4.14) 2.53 (2.17–2.95) 
 III 514 1,021 3.83 (3.35–4.39) 3.14 (2.71–3.65) 
 IV 574 1,264 3.14 (2.78–3.54) 2.62 (2.29–3.00) 
 Missing 19 44 3.45 (1.75–6.83) 3.41 (1.58–7.36) 
T-descriptor3        
  1 256 473 3.96 (3.57–4.40) 3.03 (2.72–3.38) 
  2 501 1,012 3.28 (2.99–3.60) 2.59 (2.35–2.85) 
 3 290 627 3.52 (3.17–3.91) 2.75 (2.46–3.06) 
 4 527 1,151 3.45 (3.16–3.77) 2.77 (2.52–3.04) 
 Missing 13 28 3.22 (2.50–4.16) 2.46 (1.89–3.20) 
N-descriptor3        
  0 610 1,313 3.44 (3.15–3.75) 2.67 (2.44–2.92) 
  1 145 296 3.12 (2.71–3.61) 2.44 (2.10–2.82) 
  2 490 1,007 3.60 (3.28–3.94) 2.86 (2.60–3.15) 
  3 306 585 3.68 (3.33–4.07) 2.97 (2.68–3.30) 
  Missing 36 90 2.88 (2.33–3.57) 2.20 (1.77–2.75) 
Adenocarcinoma       
Overall  3,419 9,324 2.28 (2.18–2.39) 2.00 (1.90–2.10) 
Stage at diagnosis3        
 I–II 968 2,391 2.68 (2.44–2.93) 2.17 (1.97–2.40) 
 III 598 1,575 2.44 (2.18–2.73) 2.07 (1.83–2.33) 
 IV 1,826 5,278 2.08 (1.96–2.2) 1.90 (1.78–2.04) 
 Missing 27 80 2.05 (1.24–3.40) 1.80 (1.03–3.13) 
T-descriptor3        
  1 920 2,341 2.56 (2.37–2.77) 2.14 (1.97–2.32) 
  2 914 2,656 2.12 (1.97–2.28) 1.83 (1.70–1.97) 
 3 517 1,360 2.28 (2.08–2.50) 1.94 (1.76–2.13) 
 4 1,002 2,772 2.23 (2.08–2.39) 1.96 (1.82–2.10) 
 Missing 66 195 2.08 (1.63–2.66) 1.73 (1.35–2.24) 
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Table 9. OR and 95% CI for the association between a diagnosis of lung cancer and a recent history of repeated 
fillings (≥2 fillings) of antibiotics recommended for the treatment of pneumonia, Lung Cancer DataBase Sweden, 
2009–2016 
  Exposed individuals1  OR (95% CI) 
 Cases Controls Unadjusted Adjusted2 
N-descriptor3        
  0 1,444 3,766 2.25 (2.11–2.40) 1.89 (1.77–1.98) 
  1 216 710 2.04 (1.79–2.33) 1.73 (1.51–1.98) 
  2 926 2,562 2.35 (2.19–2.52) 2.03 (1.89–2.19) 
  3 749 2,054 2.40 (2.22–2.60) 2.11 (1.95–2.29) 
  Missing 84 232 1.88 (1.53–2.31) 1.56 (1.26–1.93) 
SCLC       
Overall  1,006 2,446 2.74 (2.51–3.00) 2.25 (2.04–2.49) 
Stage at diagnosis3        
 I–II 47 116 2.75 (1.83–4.14) 1.99 (1.25–3.18) 
 III 312 654 3.52 (2.96–4.18) 2.77 (2.29–3.35) 
 IV 629 1,642 2.46 (2.20–2.74) 2.09 (1.85–2.35) 
 Missing 18 34 3.79 (1.88–7.69) 3.27 (1.41–7.59) 
T-descriptor3        
  1 119 264 3.01 (2.67–3.38) 2.41 (2.13–2.72) 
  2 170 467 2.59 (2.32–2.89) 2.13 (1.90–2.38) 
 3 148 326 2.82 (2.50–3.19) 2.28 (2.02–2.58) 
 4 541 1,322 2.74 (2.49–3.01) 2.28 (2.07–2.52) 
 Missing 28 67 2.45 (1.90–3.16) 1.96 (1.51–2.55) 
N-descriptor3        
  0 88 306 2.65 (2.38–2.96) 2.12 (1.89–2.38) 
  1 49 111 2.46 (2.10–2.87) 1.97 (1.68–2.31) 
  2 399 873 2.79 (2.52–3.09) 2.29 (2.06–2.55) 
  3 442 1,080 2.80 (2.53–3.10) 2.34 (2.11–2.60) 
  Missing 28 76 2.25 (1.81–2.80) 1.77 (1.41–2.21) 
Abbreviations: Odds ratio (OR), Confidence interval (CI), Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC).  
 
1 Individuals with repeated (≥2) fillings of prescriptions of antibiotics recommended for treatment of pneumonia as recorded in the Prescribed Drug 
Register within three years before the index date (i.e. the date of lung cancer diagnosis and the corresponding date for the matched individuals free of lung 
cancer).  
2 Adjusted for year of birth, sex, place of residence, educational level, previous diagnosis of chronic obstructive pulmonary disease, previous use of 
antibiotics recommended for treatment of pneumonia, history of any cancer, and the other TNM descriptors for the descriptor specific estimates (e.g. if 
estimating the effect of exposure in subgroups of T-descriptor, the estimate was adjusted for N- and M-descriptors).  
3 Based on the tumour-node-metastasis (TNM) classification system by the American Joint Committee on Cancer. 
 
Discussion: Infections are common in the area of tumour growth and can present as an initial 
symptom of a lung tumour. Moreover, tumours can, initially, be difficult to distinguish from 
infected loci on a lung X-ray (168-170). Consequently, our finding of a positive association 
between a diagnosis of lung cancer and a recent history of filled prescriptions was not a 
complete surprise and does not necessarily reflect inappropriate prescribing of antibiotics. 
However, with as many as 7% of the patients with lung cancer having filled four or more 
prescriptions (maximum 63) within three years before diagnosis, contrary to clinical 
guidelines, our findings indicate the absence of proper clinical reassessment and follow-up in 
some patients after undergoing treatment for pneumonia (171).  
We did not find evidence supporting a trend by stage in the magnitude of the effect size for 
the association between a diagnosis of lung cancer and a history of repeated fillings. The 
indication of the slightly attenuated magnitude of the effect size for stage IV cancer compared 
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to stage III cancer may reflect characteristics in patients with stage III disease associated with 
increased risk of infections or presence of infection-like symptoms, for example, lymph node 
involvement, spread to an ipsilateral lobe or invasion of heart or central parts of the lung (17). 
This does not have to be the case for patients with stage IV disease. However, the descriptor-
specific estimates, with no trends in the magnitude of the effect size by the T- or N-
descriptors, did not bring clarity to the indicated difference between stage III and stage IV. 
Taken together, our findings do not provide evidence that a history of repeated treatment 
cycles of antibiotics is related to diagnostic delays, at least not as reflected in increased 
likelihood of being diagnosed with a larger tumour or more advanced stage.  
Conclusion: We found that a diagnosis of lung cancer was associated with approximately a 
two-fold increase in the likelihood of a recent history of at least one filled antibiotic 
prescription. The magnitude of the effect size became more pronounced with an increasing 
number of filled prescriptions and with proximity to the diagnosis, further corroborating the 
notion that infection represents an early sign of lung cancer. Therefore, repeated antibiotic 
use may be an indicator of undiagnosed lung cancer. Our findings do not support the 
suggestion that repeated treatment cycles is associated with a diagnostic delay, as reflected by 
a more advanced disease at diagnosis. Our findings further underscore the importance to rule 




4.4 STUDY IV 
Background: Overall relative survival in lung cancer has increased in the last few decades. 
Recent improvements in diagnostic procedures and treatments have possibly affected 
different subgroups differently. 
Study population: Individuals with a first-time diagnosis of adenocarcinoma or squamous 
cell carcinoma of the lung between 1995 and 2016 as recorded in the NLCR. 
Study design: Population-based cohort study.  
Setting: Sweden. 
Exposure: A diagnosis of lung cancer (ICD-7: 1621, ICD-O-3: C34). 
Main outcome: Relative survival at one, two and five years post-diagnosis. 
Statistical analyses: Relative survival was estimated for each year between 1995 and 2016. 
This was performed for the whole cohort, as well as in subgroups defined by sex, 
histopathology, cancer stage, and smoking status. Survival for the patients with lung cancer 
was counted from the date of the lung cancer diagnosis until the date of death, emigration or 
administrative censoring (31 December 2016), whichever occurred first. The expected 
survival was derived from the general Swedish population using the life table approach.  
Results: Among the 36,935 patients diagnosed with adenocarcinoma or squamous cell 
carcinoma of the lung between 1995 and 2016 in Sweden, one-, two- and five-year age-
standardised relative survival increased from 38% (95% CI: 32–43) to 59% (95% CI: 56–61), 
21% (95% CI: 17–36) to 37% (95% CI: 35–39), and 14% (95% CI: 10–38) to 24% (95% CI: 
21–26) respectively (Figure 6). In general, the estimated relative survival increased most for 
women (Figure 6), patients with adenocarcinoma (Figure 7), patients with stage III cancer 





Figure 6. Age-standardised one-, two- and five-year relative survival estimates over calendar years overall and by sex 




Figure 7. Age-standardised one-, two- and five-year relative survival estimates over calendar years by histopathology 





Figure 8. Age-standardised one-, two- and five-year 
relative survival estimates over calendar years by 
cancer stage for patients diagnosed with 
adenocarcinoma or squamous cell carcinoma of the 
lung, Lung Cancer DataBase Sweden, 1995–2016 
Figure 9. Age-standardised one-, two- and five-year 
relative survival estimates over calendar years by 
smoking status for patients diagnosed with 
adenocarcinoma or squamous cell carcinoma of the 




Discussion: The increase in overall five-year relative survival for patients with lung cancer in 
our study mirrored the trends observed for most countries in the international CONCORD 
studies for the period 1995–2014 (98, 172).  
The more pronounced increase in relative survival that we found for women, patients with 
adenocarcinoma and never-smokers was not unexpected. In general, patients with targetable 
mutations are overrepresented among women, patients with adenocarcinoma, and never-
smokers (11, 90, 173). Consequently, it should be expected that the introduction of target 
therapies has been more favourable for these subgroups and has increased the relative 
survival to a greater extent for them compared to their counterparts.  
Confirming recent results from other European countries, we found a more pronounced 
increase in relative survival for patients with stages I–III compared to stage IV (174-176). 
The pronounced increase in relative survival for patients with stages I–III may be explained 
by the fact that the new diagnostic procedures are more frequently used in this group, 
resulting in more accurate staging and more suitable treatment for these patients (13, 19).  
The recent introduction of target therapies and immunotherapies, indicated for patients with 
late-stage NSCLC, is a probable explanation for some of the estimated increases in relative 
survival for these patients (19). Even if the indicated increase in five-year relative survival for 
patients with stage IV cancer was not particularly pronounced in terms of absolute numbers, 
it must still be considered of special interest. Previously, it was not considered reasonable that 
improvements for patients with stage IV could affect five-year survival. However, as 
indicated in our study, this may have started to change, possibly because of the new 
pharmacological treatments.  
Some of the observed increased relative survival for patients with stages III–IV disease in 
later years may also be attributed to the reclassification of the TNM system in 2010 when 
patients with pleural effusion were moved from stage IIIB to stage IV (17). This seems to 
have had a greater impact on relative survival in patients in stage III compared to stage IV.  
Conclusion: The results of this study corroborate the previously observed global trend of 
increased relative survival in patients with lung cancer over time. The relative survival had 
the most pronounced increase for women, patients with adenocarcinoma, patients with stage 




5 METHODOLOGICAL CONSIDERATIONS 
5.1 GENERAL CONSIDERATIONS 
Selection bias arises when the study population is not representative, in terms of the 
distribution of exposure status and the outcome, of the underlying source population to which 
one aims to generalise the results (177). The effect of selection bias on the effect size for the 
association will differ depending on how the composition of the study population differs from 
the underlying source population. The use of nationwide population-based registers with high 
completeness of the entire population reduced the risk of introducing selection bias in the 
studies included in this thesis.  
Misclassification bias arises when the information collected about the study subjects is 
incorrect (177). This mainly concerns exposure status and the outcome. Misclassification can 
be differential or non-differential. Non-differential misclassification is a misclassification that 
is unrelated to other study variables, while for differential misclassification, the degree of 
misclassification differs according to other variables, for example, exposure status or the 
outcome. Non-differential misclassification of a binary exposure variable leads to an effect 
size biased towards the null, namely no association. For a binary outcome variable, non-
differential misclassification will bias the effect size towards the null or not introduce any 
bias. The latter is the case in situations where some individuals with the outcome are 
incorrectly classified as not having the outcome (outcome sensitivity <100%). Non-
differential misclassification of a non-binary variable can bias the effect size towards or away 
from the null. Differential misclassification can also bias the effect size in either direction. 
Due to the high quality of the Swedish population-based registers used in the studies in this 
thesis, the risk of a substantial impact of misclassification bias was considered to be relatively 
low. The type of misclassification bias most likely to have been introduced in the studies was 
non-differential.  
Confounding can be defined as a ‘confusion of effect’ (177), meaning that the effect of the 
exposure is mixed, or confused, with the effect of another variable, leading to a bias of the 
estimated effect size. Depending on the association between the confounder and the exposure 
and the outcome, the effect size can be biased towards or away from the null. A confounder 
has to be associated with both the exposure and the outcome (Figure 10), cannot be on the 
causal pathway between the exposure and the outcome (mediator), and cannot be causally 




Figure 10. Definition of a confounder 
In this thesis, confounding was considered and handled mainly by adjusting for potential 






5.2 STUDY-SPECIFIC CONSIDERATIONS 
5.2.1 Study I 
The main limitation in study I was the short follow-up time, as the median follow-up was 
approximately four years. If there is a true inverse association, one has to consider the time 
from initiation of the treatment to the effect, mediated by altering the cellular pathways.  
Furthermore, we used an intention-to-treat approach, which does not take into account 
whether exposed individuals stopped taking the medication or whether unexposed individuals 
started taking the medication after the index date. This would have biased the result towards 
the null, namely no association. In addition, differences in healthcare-seeking behaviour 
between unexposed and exposed individuals may have biased the results in study I.  
Moreover, the lack of information on potential confounders, for example, smoking status (a 
diagnosis of chronic obstructive pulmonary disease [COPD] or filled prescription of smoking 
cessation medication was used as a proxy) and body mass index (BMI) may have resulted in 
residual confounding. 
5.2.2 Study II 
Misclassification of exposure status or the outcome are concerns in study II. Possible 
misclassification was most likely of a non-differential nature, resulting in bias towards the 
null. However, since the quality and completeness are high in the data sources, a potential 
bias would only have affected the results in a minor way. 
Another limitation is that there was no information in the data source on exposure to passive 
smoking. The lack of information on passive smoking may have resulted in a biased estimate. 
Furthermore, we did not have information on changes in smoking status after the diagnosis.  
5.2.3 Study III 
The lack of information on the indication for the prescribed antibiotics may have introduced 
misclassification bias of the exposure in study III, namely individuals filled a prescription of 
an antibiotic that was not prescribed for pneumonia. This was most likely non-differential or 
more common among individuals free of lung cancer, both of which would have biased the 
results towards the null. However, since respiratory infections are one of the most common 
indications for antibiotic use (178), this was likely to have resulted in minor misclassification 
only. In addition, differences in healthcare-seeking behaviour between the included groups 
may have biased the results in study III.  
Furthermore, the lack of information on potential confounders, for example, smoking status, 
and exposure to passive smoking and air pollution may have resulted in residual confounding.  
5.2.4 Study IV 
Assuming a trend of prolonged survival over calendar years, applying the period approach for 
the most recent years of diagnosis would have underestimated the relative survival for these 
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years. The assumption of comparability, that the patients would have experienced the same 
survival as the general population had they been free of the disease of interest, is of the 
utmost delicacy when applying the relative survival framework. As almost all of the patients 
with lung cancer are ever-smokers and therefore carry a higher risk of other diseases and 
consequently a higher risk of all-cause mortality compared to the general population, it has 
been argued that relative survival should not be used for lung cancer. However, Hinchcliffe et 
al assessed the influence of violating the comparability assumption and concluded that it does 
not have a concerning impact on the estimated relative survival (179). The prognosis for 
patients with lung cancer is poor, then the fact that they are also at increased risk of dying 




6 FUTURE PERSPECTIVES 
The observed inverse association between use of antimuscarinic medications and lung cancer 
in study I raises the question of the role of non-cancer therapies in the area of cancer. In times 
of expensive new cancer therapies, the use of existing non-cancer medications in prevention 
and treatment of cancer is an interesting and appealing idea. To study and evaluate non-
cancer therapies for prevention and treatment of cancer will be an important part of future 
cancer research.  
The differences in lung cancer between patients with and without a history of smoking 
emphasise the importance of conducting future studies to identify risk factors other than 
smoking and to reduce the occurrence of these risk factors. The survival difference by 
smoking history generates questions on underlying reasons that, at least partly, have been 
addressed in previous studies. Future studies should address how to treat patients in an 
optimal way based on information on smoking status.  
The strong prognostic value of stage in combination with a high proportion of patients with 
late-stage disease at diagnosis emphasises the importance of methods and strategies for 
earlier detection and diagnosis. Identifying indicators for early lung cancer that can work as 
red flags for general practitioners when examining patients should be a focus of future 
studies. In addition, healthcare planners and providers should consider initiating screening for 
lung cancer. 
As found in study IV, relative survival has increased in recent decades both overall and in 
subgroups defined by important prognostic factors. However, for some subgroups, the 
increases were almost negligible. In the future, it will be important to prolong long-term 
survival for patients with squamous cell carcinoma and stage IV disease as well. 
Even if we in the future can make advances in terms of early detection and prolonging 
survival after diagnosis, the most important action will be to reduce the occurrence of risk 
factors, especially tobacco smoking. Huge gains will be made in the future if we can prevent 
the adolescents of today from starting smoking. Therefore, all parts of society have to work 




7 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Varje år diagnostiseras ungefär 4000 individer med lungcancer i Sverige och ungefär lika 
många dör varje år. Lungcancer är den cancerform som i Sverige och globalt orsakar flest 
dödsfall. Många diagnostiseras i en sen fas av sjukdomen och det är sannolikt starkt 
bidragande till den höga dödligheten. Att kunna identifiera faktorer som kan minska risken 
för lungcancer, identifiera tidiga indikatorer på lungcancer, samt att bättre förstå 
överlevnaden hos patienter med lungcancer och hur överlevnaden har förändrats över tid är 
av stor vikt för att kunna minska risken för lungcancer men även för att kunna förbättra 
överlevnaden hos de som får lungcancer.  
Resultaten från studie I i avhandlingen indikerar att individer som behandlats med 
antimuskarina läkemedel mot överaktivblåsa har en lägre sannolikhet att utveckla lungcancer 
jämfört med individer som inte har erhållit denna form av behandling. Resultaten i studie I 
genererar tankar och hypoteser om effekter på cancer av läkemedel som inte utvecklats för att 
behandla cancer.  
I studie II såg vi att patienter med lungcancer som aldrig har rökt var äldre, samt att kvinnor, 
EGFR mutation, adenocarcinom och cancer i stadie IV var överrepresenterade hos patienter 
som aldrig rökt. De som aldrig hade rökt hade också en längre överlevnad efter diagnos 
jämfört med rökarna. Dessa resultat bidrar till tidigare resultat från andra studier som har sett 
skillnader mellan rökare och icke-rökare, samt att det understryker vikten av att bättre förstå 
dessa skillnader för att kunna förebygga lungcancer hos individer som aldrig har rökt och på 
ett bättre sätt behandla patienter baserat på rökstatus.  
På resultaten från studie III ser man att det föreligger ett samband mellan lungcancer och 
tidigare uthämtning av antibiotika för behandling av lunginfektioner. Styrkan på sambandet 
ökade med närhet till diagnosen och med antalet uthämtningar under treårsperioden som 
föregick diagnosen. Dessa resultat antyder att antibiotikaanvändning, speciellt upprepade 
uttag, kan vara en indikator för tidiga symptom på lungcancer som skulle kunna användas 
inom primärvården för att kunna upptäcka fler patienter redan i ett tidigt skede.  
I studie IV fann vi att den relativa överlevnaden hos patienter med lungcancer har ökat över 
tid från 1995 till 2016. Den tydligaste ökningen sågs bland patienter med cancer som ännu 
inte har spritt sig utanför lungorna. Dessa skillnader beror sannolikt på att de förbättringar 
som gjorts inom diagnostik främst har påverkat patienter i denna grupp, samt att en stor del 
av dessa patienter även har dragit nytta av nya behandlingar. Kunskapen om hur 
överlevnaden har förändrats över tid, och skillnaderna i förändring mellan olika grupper, kan 
bidra till att bättre förstå effekter av genomförda förändringar men även hjälpa till att belysa 
var framtida insatser bör fokuseras för att framöver kunna förbättra överlevnaden hos flera 
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